Browsing by Author "Heneghan, Michael A."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
    (2024) Kowdley, Kris V.; Bowlus, Christopher L.; Levy, Cynthia; Akarca, Ulus S.; Alvares-da-Silva, Mario Reis; Andreone, Pietro; Arrese, Marco; Corpechot, Christophe; Francque, Sven M.; Heneghan, Michael A.; Invernizzi, Pietro; Jones, David; Kruger, Frederik C.; Lawitz, Eric; Mayo, Marlyn J.; Shiffman, Mitchell L.; Swain, Mark G.; Valera, Jose Miguel; Vargas, Victor; Vierling, John M.; Villamil, Alejandra; Addy, Carol; Dietrich, Julie; Germain, Jean-Michel; Mazain, Sarah; Rafailovic, Dragutin; Tadde, Bachirou; Miller, Benjamin; Shu, Jianfen; Zein, Claudia O.; Schattenberg, Jorn M.
    Background Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.
  • Thumbnail Image
    Item
    The effects of elafibranor in people with primary biliary cholangitis: a plain language summary
    (Taylor and Francis Ltd., 2025) Kowdley, Kris V.; Bowlus, Christopher; Levy, Cynthia; Akarca, Ulus S.; Alvares-da-Silva, Mario Reis; Andreone, Pietro; Arrese, Marco; Francque, Sven M.; Heneghan, Michael A.; Invernizzi, Pietro; Jones, David; Lawitz, Eric; Mayo, Marlyn J.; Swain, Mark G.; Vargas, Victor; Vierling, John M.; Villamil, Alejandra; Addy, Carol; Dietrich, Julie; Mazain, Sarah; Taddé, Bachirou; Miller, Benjamin; Shu, Jianfen; Zein, Claudia O.; Roberts, Carol; Wright, Gail; Schattenberg, Jörn M.
    This is a plain language summary describing the phase 3 clinical trialcalled ‘ELATIVE®’. Primary biliary cholangitis (PBC) is a rare disease of the liverthat can get worse over time and can be potentially life threatening. Livingwith PBC can also reduce a person’s quality of life. There are currently notmany treatment options available for PBC. The ELATIVE® clinical trial testedhow well a potential new treatment called ‘elafibranor’ works in treatingpeople with PBC.